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Proteolytic Amyloid-β Chaperones 
in Alzheimer’s Disease
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Abstract
This chapter attempts to explore protective role of chaperone proteins in the 
neurodegenerative diseases caused by amyloidosis. These chaperones prevent amy-
loid pathology either directly, through chemical interactions with amyloidogenic 
species to mediate their refolding, solubilization and degradation, or indirectly, by 
scavenging reactive oxygen species produced as by-products of amyloid aggrega-
tion. Here we focus on structural and morphological changes during aggregation of 
amyloids which have been identified using Nuclear magnetic resonance spectros-
copy, X-ray crystallography, Electron microscopy, Atomic force microscopy and 
other biophysical techniques as well as interactions between chaperone proteins 
and amyloid moieties. Non-proteolytic chaperones mediate amyloid clearance 
and metabolism through conformational changes due to proximity binding. In 
this chapter, we delineate these interactions as well as the molecular mechanism of 
chaperones used to sequester ROS products of amyloidosis with focus on amyloid-β 
peptides associated with the Alzheimer’s disease.
Keywords: amyloid-β, structural biology, aggregation, chaperone, neuroprotection, 
Alzheimer’s disease
1. Introduction
Abnormal deposition of amyloids or “Amyloidosis” is hallmark of several 
chronic cerebrovascular diseases including neurodegeneration culminating into 
dementia. Efforts to develop targeted drugs against amyloids have been hindered 
since there is no universal mechanism that leads to protein misfolding or aggrega-
tion, and the aggregates usually do not correspond directly to clinical symptoms 
of the diseases. A clearer understanding of molecular interactions of amyloids can 
drive the ongoing therapeutic efforts to prevent aggregation of nascent amyloids 
into pathological species and to design timely interventions. In addition to aging, 
precursor mutations in genes and proteins, gene multiplication, expansion of 
amyloidogenic sequences, and xenobiotics such as air pollutants are risk factors 
usually associated with amyloidosis disorders [1]. There are different amyloido-
genic species causing a variety of neuropathic diseases such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD), Poly-glutamine disorders like Huntington disease 
(HD), Prion diseases including Creutzfeldt-Jakob disease, Lewy body disease, 
Amyotrophic Lateral Sclerosis (ALS) as well as metabolic diseases such as type II 
diabetes (T2D) and corneal dystrophy to name a few [2]. AD is a pandemic form of 
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dementia caused due to improper aggregation of amyloidogenic proteins-amyloid-β 
(Aβ), which is a cleavage product of amyloid precursor protein (APP) and tau, 
stabilizes microtubules in neurons [3]. Prognosis is also closely associated with 
aggregation of α-Synuclein (αS) protein into Lewy bodies usually concentrated in 
presynaptic terminals [4]. Human islet amyloid polypeptide (IAPP), also known as 
amylin, is secreted along with insulin from pancreatic β-islet cells. IAPP rich amy-
loid plaques, facilitated by insulin resistance, are hallmarks of T2D [5]. β-sheeted 
infectious isoform of cellular prion protein (PrP) causes transmissible spongiform 
encephalopathy (TSE), broadly known as prion disease [2].
In this chapter, we review various structures and conformations attained by Aβ 
peptides during the process of aggregation. We begin with introducing different 
morphologies and conformations attained by amyloids during this process. We 
outline mechanisms of amyloid pathology, either directly mediated by aggregates 
or indirectly through generation of oxidative stress. We have briefly alluded to 
chaperone functions of Heat shock protein (Hsp) family and their interactions 
to different amyloid structures as well as intracellular protease mechanisms. It is 
important to note that such intracellular proteases are almost entirely inefficient in 
dealing with large insoluble plaques. Here we emphasize on additional endogenous 
proteins which show potential as chaperones, albeit through different mecha-
nisms. Towards the end, we discuss the role of oxidative stress in accelerating 
AD pathology and the effect of Aβ interactions with metal species. Mechanisms 
to alleviate oxidative stress and their possible protective role in AD have been 
discussed.
2. Structural and biophysical basis of amyloid aggregation
Membrane glycoprotein APP is cleaved by β-secretase and γ-secretase enzymes 
generating 36–49 residue long peptides, among which amyloidogenic Aβ(1–40) and 
Aβ(1–42) are well-known culprits in AD [6]. Unstructured monomeric amyloids 
polymerize to form fibrillar structures with characteristic cross-β morphology 
formed by in-register β-sheets which align parallel to the fibrillar axis whereas 
perpendicularly extended side-chains pack closely to form tight steric zippers [2]. 
Nuclear magnetic resonance (NMR) spectroscopy studies on amyloid monomers 
or fibrillar structures to identify characteristic dynamic structural features. X-ray 
crystallographic studies have helped in identifying structural motifs through fiber 
diffraction and mass-per-length studies through EM provide information regarding 
specific symmetries identified in filaments. NMR models of Aβ monomeric peptides 
show predominantly α-helices with propensity to convert into β-sheets [6]. The 
α-helical conformation is also observed among on-pathway transient intermediates, 
possibly mediated by interactions of hydrophilic N-terminal residues [7]. These 
intermediates then give way to β-sheet conformation in higher oligomeric species 
which eventually transition into mature fibrils. In vitro aggregation of Aβ monomers 
into fibrils can be carefully curated to obtained different fibril morphology. In solid 
state nuclear magnetic resonance (ssNMR) spectra, cross-peaks originating from 
hydrophobic core and C-terminal regions within amyloid fibrils, prepared without 
seeding indicate presence of polymorphs. Formation of homogenous fibrils from 
Aβ(1–42) seeds precludes aggregation of Aβ(1–40) [8].
αS binds to neuronal membranes in a highly α-helical state as opposed to the 
unfolded monomeric conformation [7]. The antipathic N-terminal sequence has 
tendency to form α-helical conformation, central region from aa 61–95 is highly 
hydrophobic and amyloidogenic, and the C-terminal domain provides flexibility 
to the protein without attaining any specific structure [7]. Prefibrillar αS shows 
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conformational plasticity and the soluble monomers combine to form unstable 
dimeric molecules which further aggregate into higher oligomers and fibrils. IAPP 
structure in detergent micelles shows a helical conformation kinked around residue 
His18 at neutral pH and an extended α-helix in acidic conditions; thus the ability to 
attain specific conformation also depends on its chemical environment [5].
2.1 Morphological differences in amyloid aggregates
Disordered or misfolded monomers can convert into a range of amyloid species, 
e.g., spherical oligomers, amorphous aggregates, annular oligomers, protofibrils, 
inclusion bodies or insoluble fibrils, based on the pathological pathways (Table 1). 
Dynamic intermediate oligomers form transient structures facilitating on-pathway 
conversion from misfolded monomers to fibrils. The spherical and annular aggre-
gates get generated off-pathway and contribute highly to amyloid mediated neuro-
toxicity [2, 9]. The Lewy bodies formed by αS are example of intracellular amyloid 
inclusions [10]. Formation of a specific aggregated form is usually controlled by pro-
cess of nucleation. In primary nucleation, seeds are formed by spontaneous aggrega-
tion of monomers followed by fibril elongation, whereas fragments from mature 
fibrils recruit monomers to facilitate the polymerization in secondary nucleation pro-
cess. However, this process is specific to monomeric species; seeding with Aβ(1–42) 
fibrils does not contribute to aggregation of Aβ(1–40) [8]. Comparison between 
kinetic profiles of seeded and non-seeded Aβ(1–40) suggest that aggregation follows 
the seeded fibrils template [8]. Monomeric Aβ(1–40) samples form striated ribbons 
under constant agitation, and twisted fibrils under undisturbed conditions [11]. 
NMR can also be used to study kinetics of oligomer interactions by utilizing the 
constant exchange of detectable monomers with other invisible oligomeric species, 
through saturation transfer difference (STD) experiments [12]. Amyloid fibrils 
show protease resistance and are insoluble in detergents. However, their affinity to 
small lipophilic molecules is amenable for detection through biophysical assays using 
Congo red and thioflavin dyes [13]. These fluorescent dyes can be used to quantify 
β-sheet rich amyloid fibrils under laboratory conditions where fluorescent intensity 
linearly correlates with fibril formation [14]. Morphology of amyloid fibrils can be 
studied using transmission electron microscopy (TEM) by observing diffraction 
patterns. Whether fibrils form a ribbon-like or a striated pattern, can be calculated 
by mass-per-length constraints [15]. Different amyloid structures can be categorized 
Amyloid 
structure
Structure/symmetry Toxicity Relevance Refs.
Monomer Disordered, random coil Non-toxic On 
pathway*
[20]
Small oligomers Rich in β-sheet (spherical, annular, 
ADDLs)
Toxic On pathway [21, 22]
Amyloid 
inclusions
Amorphous aggregates Non-toxic Off 
pathway
[2, 23]
Protofilaments Homogenous, up to 200 nm long Toxic On pathway [24]
Fibrils Cross-β Non-toxic On pathway [25]
Plaque Amorphous meshworks, fibril 
bundles, amyloid stars
Non-toxic — [26]
*On-pathway structures are intermediates involved in aggregation of amyloids into fibrils.
Table 1. 
Summary of amyloid structures observed in AD.
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based on symmetry and periodicity with these methods [16]. Aβ40 fibrils structure 
have either 2-fold (2A) or 3-fold (3Q ) rotational symmetry with a twisted morphol-
ogy with periodicity of 120 ± 20 nm, and roughly 8 nm width [2, 11]. IAPP fibrils 
also lead to formation of striated and twisted ribbons [11].
2.2 Structural properties of amyloid aggregates
Basic structural architecture of amyloid fibrils consists of a characteristic 4.7 Å 
repeat through the cross-β structure [2]. Still, there exist some variations in mor-
phology of different Aβ fibrils; the C-terminus in Aβ(1–40) is hidden within the 
core, while the corresponding residues are exposed on the surface of Aβ(1–42) [10]. 
Solid state NMR studies of amyloid fibril structures employ 2D dipolar-assisted 
rotation resonance (DARR) experiments and frequency selective rotational-echo 
double resonance (REDOR) experiments along with distance measurements 
between 13C-13C and 13C-15N nuclei [8]. Studies of Aβ(1–42) fibrils using ssNMR 
suggested unidirectional protofibril growth with two molecules coming together 
to form parallel intermolecular β-sheets. The ssNMR structure of homogeneous 
Aβ(1–42) fibrils (PDB ID: 2MXU) exhibits triple-β-strands encompassing residues 
12–18, 24–33 and 36–40 respectively, connected by coil-and-turns at residues 
19–23 and 34–42 [8]. The other structure of Aβ(1–42) fibrils with oxidized Met35 
(PDB:2BEG), suggests structural inhomogeneity in N-terminal residues from 1 to 
17 and presence of two β-strands in residues 18–26 and 31–42, respectively [17]. 
The AD related Aβ(1–42) polymorph shows double-horseshoe like cross-β structure 
where N terminus of monomeric Aβ(1–42) has L shape and the C terminus takes 
an S-shape. The structure comprises five in-register parallel strands with each fibril 
layer comprising of two molecules with hydrophobic side chains buried maximally 
[16]. In addition to hydrophobic core, parallel β-sheets also show polar zipper inter-
actions through intermolecular hydrogen bonds. A recent 4.0 Å resolution ssNMR-
cryoEM hybrid structure (PDB ID: 5OQV) of intertwined Aβ(1–42) protofilaments 
showed an approximate 21 screw helical symmetry with 4.67 Å rise [18]. This impli-
cated step-wise shift between the subunits is similar to tau dimers. Three hydro-
phobic clusters involving Ala, Val, Phe, Leu, Ile, and Met residues expand along the 
fibril axis and contribute to overall stability of fibrils [18]. Tertiary interactions in 
Aβ(1–42) fibrils are different compared to Aβ(1–40) fibrils owing to differences in 
side-chain packaging in hydrophobic core of protofilaments [17]. The N-terminus 
of Aβ(1–40) peptides is disordered and highly prone to proteolysis whereas the 
ordered region from tyrosine residue onwards acquires a double-layered structure 
with a “β-arch” motif where two β-strands are separated by a short loop [19]. This 
motif is stabilized by formation of a salt bridge between Asp23 and Lys28 across the 
bend. Interactions between Lys28 and Ala42 observed in these fibrils differ to those 
found in Aβ(1–40) [8]. Similarly, salt bridges between Asp1 and Lys28, Asp7 and 
Arg5, Glu11 and His6 and His13, and Asn-Gln ladders further contribute to stability 
of the Aβ(1–42) fibril structure [16, 18]. Point mutations introduced in basic amino 
acid sequences lead to varied fibril architecture compared to the wild-type Aβ40 
fibrils [2].
NMR structure of tau monomers shows detectable propensity to β-sheet, 
poly-proline helices and transient α-helical conformations. Aggregation of the 
R3 fragment consisting of 26 amino acid residues is strongly associated with 
formation of fibrils in the presence of polyanions as well as during self-assembly 
of pristine tau [7]. Phosphorylation of serine and threonine residues stabilize 
the α-helical conformation. αS fibrils acquire an overall assembly that mimics a 
Greek key as seen in atomic resolution structure of purified protein [7].
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2.3 Role of amyloidosis in AD pathology
Amyloidosis in cerebrovascular system is mediated through aggregation of 
wild type proteins as the consequence of multivalent interactions in intrinsically 
disordered proteins or regions of proteins, mutations in amyloidogenic precur-
sors, expansion of repeats in the amyloidogenic sequences, actions of proteases 
or chemical modifications on the precursor sequences, overexpression of the pre-
cursor, liquid–liquid phase separation, actions of small metabolites or age-related 
cell death [27–31]. The number of human proteins capable of causing amyloidosis 
has exceeded 50 and are associated with many neurological disorders based of 
variations in the disease precursors [2]. Different oligomeric and morphologically 
distinct species affect cells and tissues in different manner. Amyloid oligomers 
can be cytotoxic with the long-term potentiation disrupting membranes to cause 
ion permeability and homeostasis imbalance [2]. Fully matured fibrils contribute 
to the disease by disturbing lipid membranes and thus interfere with the general 
membrane bound cellular organelles, or by forming physical barriers which dis-
rupt inter-cellular communications [2]. Structural inhomogeneity was observed 
in fibrils from the different clinical variants of amyloids in AD. Differences in 
morphology of Aβ aggregates can change the phenotype observed in different 
forms of AD. While a single Aβ structure is found in brain cortex in the cases 
of typical prolonged duration AD, different polymorphs are found in the cases 
of rapidly progressive form of AD [32]. There are six isoforms of tau protein in 
brain and CNS, longest one containing a stretch of 441 amino acids, with high 
tendency for phosphorylation and self-assembly. Tau filaments cause different 
tauopathies, including neurofibrillary tangles in AD [7]. Neurofibrillary tangles 
and neuropil threads are predominantly tau aggregates localized in neuronal cell 
bodies and processes, respectively, whereas the mature Aβ plaques are present 
extracellularly [33].
2.4 Toxicity of amyloid aggregates
Aβ(1–42) is more potent fibrillogenic Aβ variant in human brain, yet its con-
centration accounts for only about 5–10% of Aβ(1–40) concentration produced 
[33]. Accumulation of Aβ(1–42) in brain and cerebrovascular system due to its 
aggregation propensity, and by extension, the relative ratio of Aβ(1–42): Aβ(1–40) 
is a biomarker for AD [33]. Aβ(1–40) fibrils are less toxic compared to Aβ(1–42) 
fibrils which show differential toxicity and Aβ(1–43) fibrils are most cytotoxic 
[10]. Soluble Aβ in the form of low-n oligomers, Aβ-derived diffusible ligands 
and protofibrils are among major toxic contributors towards AD pathology [34]. 
Interactions of oligomeric species with other molecular complexes, metal ions and 
cellular membranes also impact the extent of their toxic effects in brain. N-terminus 
truncated Aβ peptides (Aβ(n–42), where n can vary from 2 to 11) are highly toxic 
and are usually present in Aβ deposits in AD brain [7]. Peptides cleaved at positions 
3 or 11 are prone to pyroglutamylation and prominent components of Aβ deposits, 
likely owing to their resistance to proteolytic degradation [35]. αS is a major com-
ponent of Lewy bodies and neurites causing neurotoxicity through dopaminergic 
mechanism and these aggregates are key identifiers for PD and Lewy body demen-
tia [7]. Detection of αS aggregates early in peripheral nervous system can serve as 
early biomarkers before motor disabilities develop in PD patients [36]. Horizontal 
transfer of amyloid aggregates and oligomers between cells also contributes to 
propagation of disease pathology [37]. IAPP oligomers can impair insulin secretion 
in pancreatic cells and cause cell death and cellular uncoupling [7].
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3. β-Amyloid chaperones
The main function of molecular chaperones is to facilitate their protein targets 
acquire proper functional conformation or fold into correct oligomeric assemblies 
[38]. Several proteins have been shown to bind misfolded amyloids and inhibit 
amyloid aggregation or promote refolding of polymorphs. They usually play other 
physiological roles, yet show tendency to prevent amyloidosis under specific 
stimuli. We will discuss some of these non-proteolytic chaperones in more detail 
below. Additionally, albumin binding to polymeric Aβ, α1-antitrypsin, immuno-
globulins A and G are endogenous human cerebrospinal fluid (CSF) proteins with 
capability to control amyloid formation, although the inhibitory activity is lesser by 
two orders of magnitude compared to plasma [39].
3.1 Heat shock proteins
Heat shock proteins (Hsp) are the most commonly known chaperones in 
human body, divided into five classes Hsp70, Hsp90, Hsp60, Hsp40, and small 
Hsps, differing in protein size. Chaperones in Hsp60 and Hsp70 family mediate 
folding, Hsp33 family hold partially folded proteins till other chaperones or degra-
dation system can act, and Hsp104 promotes solubilization of aggregated proteins 
[38]. Mutations in αA- or αB-crystallin and other small heat shock proteins have 
been linked to increased risk of certain amyloidosis conditions [40]. Hsp70 and 
Hsp90 are capable of utilizing ATP molecules to perform energy costly unfolding 
of stable misfolded aggregates and then convert them into properly folded confor-
mations. Similarly other members like Hsp110 can act as disaggregases to forcibly 
solubilize preformed fibrillar aggregates [41]. Hsp70 recognizes KFERQ motif 
in proteins to mediate degradation by transporting them to lysosomal compart-
ments inside the cell, a typical example of chaperone mediated autophagy [41]. 
Disaggregation machinery in humans mainly involves proteins from Hsp family 
namely, Hsp110, Hsp105, Hsp100, and Hsp70/40 co-chaperone cognates [41]. 
Proteins in Hsp40 co-chaperone family, mainly DnaJB6 and B8, can decrease the 
aggregation of polyglutamine peptides in HD in addition to modulating Hsp70 
activity [41]. Binding of misfolded proteins and interaction with ATPase domain 
of Hsp70 are achieved via the highly conserved J domain. Anti-aggregation activity 
of Hsps, especially Hsp70, is at least partially dependent on presence of ATP [42]. 
ADP-bound forms of Hsp70 is generated as a result of the ATP hydrolysis by its co-
chaperones. This form has high affinity for the hydrophobic residues in misfolded 
peptides and holds the unfolded ensemble till it spontaneously achieved proper 
conformational populations. Small Hsps (12–42 KDa) do not require ATP since 
they usually function as holdases and assist other proteins in Hsp chaperone com-
plex [41]. Hsp104 is part of proteostasis network which regulates prion assembly 
in yeast, Hsp110 is its human counterpart which facilitates chaperone function of 
Hsp70 and Hsp40 [43]. Hsp90 and its co-chaperones interact with tau and a close 
control on their interaction can cause the oligomers to turn into benign species 
instead of toxic aggregates [44]. Free Hsp90 binds and releases substrates in its 
monomeric extended form, and attains a dimeric ATP-bound closed conformation 
mediate by co-chaperones p23/Sba1, Hsp70/90 organizing protein (HOP), Cdc37 
and other proteins [41, 45]. Hsp60 chaperonins are mainly located in mitochon-
dria and form heptameric, double ring complexes which provide isolated environ-
ment for protein folding with co-chaperonins Hsp10 forming the lid of this cavity. 
Unlike Hsp60, the cytosolic chaperonins in neurons such as TCP-1 Ring Complex 
(TRiC or CCT), do not require co-chaperones for their function and form a double 
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ring complex with each ring consisting of eight subunits. Hsp60 can interact with 
mutant αS in PD brain [41]. B-chain of monomeric or dimeric insulin can bind to 
IAPP monomers, thus preventing their aggregation [7]. Presence of chaperone 
proteins such as Hsp27 (HSPB1), αB-crystallin (HSPB5) and Hsp70 (HSPA1A) 
can decrease cell toxicity, possibly by binding Aβ oligomers and converting them 
to larger less toxic aggregates, however it not clear whether they bring about any 
change in secondary or tertiary structure [44]. HSPA6 is induced in neurons post 
heat shock, unlike other members of this family HSPA1A and HSP8, thus has a 
unique probable role as a human neuronal chaperone [46]. Hsp70 and Hsp90 have 
differential roles in case of inflammation and macrophage recruitment. Hsp90 
can also stabilize neurotoxic proteins and should be carefully controlled to achieve 
required therapeutic outcomes.
3.2 Intracellular degradation machinery
Molecular chaperones are capable of binding and folding intracellular soluble 
amyloid aggregates, however solubilization of amyloid plaques is out of scope 
for these proteins. While these chaperones may not be able to completely reverse 
neurodegenerative symptoms, they play crucial anti-apoptotic functions through 
protein folding and degradation of unfolded or misfolded proteins. There are 
fundamental mechanisms underlying a chaperone function, namely, unfolded 
protein response (UPR), protein compartmentalization, heat shock response, 
chaperone-mediated autophagy and lysosome system, ER associated degradation 
(ERAD) and ubiquitin-proteasome system (UPS) [46]. Extracellular chaperones 
mediate proper protein folding and refolding by providing isolated environment 
or through intermolecular interactions. If proper folding cannot be achieved, they 
may play a role in mediating intracellular proteasomal degradation or microglial 
digestion of unfolded protein fragments. Cytosolic chaperone systems like Hsp70 
and Hsp40, comprising heat shock cognate 70 (Hsc70), and their interacting pro-
teins like C-terminus of Hsc70-interacting protein (CHIP) can mediate targeting 
of misfolded proteins to proteasome machinery [38]. Intracellular pathways for 
degradation of misfolded proteins include the UPS, 26S proteasome and lysosome-
mediated phagocytosis [9]. Hsp70 recruits misfolded proteins, especially αS, for 
degradation by directing them to proteasomes or autophagy-lysosomal pathway 
[44]. UPS comprises of a cascade of enzymes E1 (Ub activating enzyme), E2 (Ub 
conjugating enzyme) and E3 (Ub ligase) facilitating binding of ubiquitin (Ub) 
to target proteins. Ligase enzymes in this cascade can employ chaperone proteins 
such as Hsc70 for recognition of exposed hydrophobic regions misfolded peptides 
and together mediate proteolysis of misfolded intracellular proteins. E4 enzyme 
from UPS can recruit additional Ub molecules to the protein substrate which can 
be either directed for degradation or other protein interactions based on their 
topology [41]. 26S proteasome particles degrades polyUb-conjugated proteins 
with the help of its two 19S regulatory particles responsible for recognition and 
de-ubiquitination and a 20S core particle through which proteolysis of these sub-
strates into short peptides is mediated [41]. ERAD withholds misfolded proteins 
from continuing with on-going cargo to golgi apparatus for further downstream 
processes. UPR is initiated by migration of transcription factors to the nucleus 
causing upregulation of ER chaperones-encoding gene expression in response 
to increasing in unfolded proteins, such as Aβ aggregates in neuronal ER, which 
require assistance of chaperones present in the ER [47, 48]. Reduction in UPS 
proteolytic activity is linked with disease pathology in AD, PD, ALS, HD as well 
as TSEs.
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3.3 Non-proteolytic amyloid chaperones
Aging is a major risk factor for many neurodegenerative diseases. The UPS 
system is known to get deregulated with increase in neuronal age and therefore 
offers less resistance to pathological protein aggregates. Proteins such as Human 
serum albumin show competitive binding towards Aβ oligomers, with its different 
domains binding to many oligomeric molecules [12]. It binds almost 90% of plasma 
Aβ peptides potentially through dual binding mechanism involving Aβ(1-40) 
monomers and protofibrils likely utilizing residues involved in fibril formation.
Here we suggest non-proteolytic endogenous proteins which show potential 
as AD therapeutics directed against Aβ, namely, Lipocalin-type prostaglandin 
D synthase (L-PGDS, also known as β-trace), apolipoprotein E (ApoE), α2 
macroglobulin (α2M), haptoglobin and clusterin as alternatives to intracellular 
Aβ degradation machinery. These proteins have been sporadically studied for 
their holdase or transporter activity, yet their Aβ chaperone function is still 
unexplored. L-PGDS is the second most abundant protein in human CSF after 
albumin [49]. It exhibits dual functions, as a lipophilic ligand transporter in cells 
and as isomerase in arachidonic acid pathway to convert prostaglandin H2 to 
prostaglandin D2 [50]. L-PGDS plays protective roles in different neurological 
diseases including genetic demyelinating disease, brain injuries and multiple 
sclerosis [51]. It plays protective role against cerebral ischemia as well [52]. It 
promotes recruitment of astrocytes and glial cells to the source of injury [53]. 
Early stress stimulus can upregulate L-PGDS suggesting its unknown, yet novel 
stress protection mechanism. L-PGDS deficient mice showed additional neuro-
nal apoptosis strongly indicating its important protective function in neurons 
and surrounding oligodendrocytes [51]. L-PGDS binds to various Aβ peptides 
including fibrils and is colocalized in Aβ plaques [54]. Furthermore, Aβ is physi-
ologically secreted to CSF under normal conditions where L-PGDS is abundant. 
L-PGDS ratio in CSF:serum is already identified as early biomarker for detection 
of potential damage to blood–brain barrier and quantifying its complex with 
transthyretin in CSF is also suggested to be a possible diagnostic marker [55]. 
L-PGDS colocalizes with amyloid plaques and mediates inhibition of aggregates 
through cysteine residue [54]. Based on previous studies and our own findings, 
we posit that secreted L-PGDS binds to monomeric and prefibrillar Aβ and 
inhibits amyloid aggregation in synergy with its ability to break down mature 
fibrils.
α2M is also an extracellular glycoprotein showing potential chaperone proper-
ties. It can prevent proteases from hydrolyzing proteins and mediates Aβ clearance 
through formation of α2M/protease complexes [56]. It protects cells from apoptosis 
through receptor interactions. α2M selectively binds proteins in non-native confor-
mations and in process prevents their aggregation [56]. α2M decreases with age and 
its clearance mechanisms for Aβ get impaired [57]. A2M gene polymorphisms are 
associated with sporadic AD in some populations and α2M is also present in amyloid 
plaques [58]. ApoE isoforms E2, E3 and E4 can delay amyloid aggregation through 
differential activity as extracellular chaperones [59]. The suggested role of apoE4 
as pathological chaperone is partly due to its role in delaying fibril formation from 
Aβ monomers leading to increase in toxic oligomeric species [60]. Isoform E3 and 
E2 show binding affinity to oligomeric Aβ as well, thus decreasing their neurotoxic 
effects [61]. Clusterin, or apolipoprotein J, is also extracellularly secreted and 
moonlights as a chaperone upon cellular stress stimulus [62]. Very similar to sHsps in 
its chaperone activity, clusterin preferentially interacts with off-pathway aggregates 
which are highly toxic and prone to precipitation [63]. Haptoglobin is very similar 
to α2M as an extracellular chaperone glycoprotein, though is activated in acidic 
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environment and interacts with prefibrillar amyloids to prevent further aggrega-
tion [64]. These endogenous proteins and many others may play very important yet 
undiscovered role to maintain proteostasis in physiological environment.
Ig antibodies such as aducanumab, targeting specific oligomeric forms of Aβ 
have already reached clinical trials, showing promising therapeutic effects focus-
ing on delaying cognitive decline. However recent withdrawals of some of these 
antibodies like bapineuzumab and solanezumab, have forced scientists to look for 
more robust options [65]. Enzymes such as insulin degrading enzymes, neprilysin, 
cathepsin B are capable of degrading amyloidogenic peptides. Enzymes belong-
ing to peptidyl-prolyl cis/trans isomerase (PPIase) family, e.g., CypB, can convert 
Chaperone Function Amyloid  
species
Chromosomal 
and cellular 
location
Brain 
expression 
levels 
(HPA) [66]
Refs.
Hsp70  
(DnaK)
Holdase Nascent 
amyloids and 
oligomers
6p21; 
intracellular
66.3 TPM [42, 67, 
68]
Hsp90 Holdase Nascent 
amyloids and 
oligomers
14q32; 
intracellular
1021.5 TPM [69, 
70]
Hsp40  
(DnaJ)
Holdase; 
disaggregase 
in ternary 
complex
Higher order 
aggregates
19p13; 
intracellular
110.5 TPM [71]
αB crystallin 
(Hsp27)
Holdase Amyloid  
fibrils
11q23; 
intracellular, 
membrane
1888.7 TPM [72]
Hsp110 Disaggregase; 
holdase
Prefibrillar 
oligomers
13q12; 
intracellular
109.4 TPM [73]
Hsp28 (sHsp) Holdase Unfolded or 
misfolded 
proteins
7q11; 
intracellular
98.7 TPM [74]
Hsc70  
(HSPA8)
Chaperone 
mediate 
autophagy
Nascent 
polypeptides
11q24; 
intracellular
1119.0 TPM [75]
Hsp60 Chaperonin Early 
oligomeric 
species
2q33; 
intracellular
141.6 TPM [76, 
77]
STUB1  
(CHIP)
Ubiquitin-
mediated 
protein 
degradation
Misfolded 
protein 
aggregated
16p13; 
intracellular
137.7 TPM [78]
L-PGDS  
(β-trace)
Aggregation 
inhibitor
Monomers, 
fibrils
9q34; secreted 1224.7 TPM [54]
Clusterin  
(ApoJ)
Stabilizer Senile 
plaques/
diffusible 
aggregates
8p21; secreted 10875.4 
TPM
[79]
α2-Macroglobulin Inhibitor Prefibrillar 
species
12p13; 
extracellular
172.0 TPM [80]
Table 2. 
Mode of function of endogenous amyloid chaperones.
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proline containing peptides from cis to trans conformational isomers thereby 
facilitating their folding process [47]. Some inherently amyloidogenic proteins 
such as PrP, hTTR and BRICHOS-domain containing proteins can paradoxically 
also inhibit aggregation of other amyloids. BRICHOS-domain containing protein 
ITM2B (Bri2) is a CNS membrane protein which shows chaperone functions for 
amyloids by binding to tyrosine and other charged residues [43]. Tetrameric form 
of Transthyretin (TTR) can also prevent aggregation of amyloid oligomers [44]. In 
recent years, some small molecules have also been put forward as possible inhibi-
tors of amyloid aggregation—such as polyphenols, e.g., epigallocatechin gallate 
(EGCG), curcumin, resveratrol, etc. [7, 12]. Understanding inhibition mechanisms 
of non-proteolytic endogenous chaperone proteins and other molecules is very 
crucial to develop therapies targeting amyloid aggregates in AD (Table 2).
4. Oxidative stress
Oxidative stress in human body is mainly mediated by reactive oxygen species 
(ROS) including hydrogen peroxide (H2O2), hydroxyl free radical (•OH), superoxide 
(O2
•−), peroxyl (•OOR), hypochlorous acid (HOCl), nitric oxide (NO), peroxyni-
trite (ONOO−) and other reactive nitrogen species. Increase in concentration of 
these reactive species can trigger downregulation of antioxidant enzymes such as 
superoxide dismutase (SOD), glutathione peroxidase, catalase, thioredoxin and 
small molecules such as melatonin and coumarin [81]. Endogenous sources of ROS 
include components in mitochondrial electron transport chain and NADPH oxidase, 
which can trigger pathological responses leading to lipid peroxidation, DNA dam-
age and cell death mediated by toxic products. Amyloid plaques have been shown 
to contain multi-fold concentrations of metals like iron (Fe), copper (Cu) and zinc 
(Zn) [81]. Intracellular Aβ can also trigger production of highly toxic molecules 
such as 4-hydroxyl-2,3-nonenal (HNE) and malandialdehyde through interactions 
with Fe or Cu which can catalyze Fenton reactions to generate more OH− ions. 
Hydroxyl radicals can also be generated from other brain ROS through Haber-Weiss 
reaction, particularly within mitochondria which are most prone to such oxida-
tive damage [82]. Such ROS are generated as by-products of amyloid aggregation 
and are involved with metallobiology of dementia. High concentrations of Fe in 
brain have drastic effects in cases of dementia leading to cognitive decline through 
interactions with brain amyloids [83]. Metal ions are crucial for many brain func-
tions and Fe and Cu even possess active sites for binding antioxidant SOD. However, 
increase in concentrations of some of these metals can cause high levels of toxicity. 
Twenty percent of cases in familial ALS is affected by mutation in a single enzyme 
SOD1 functionally affected by Cu/Zn [83]. Metal ions have propensity to bind high 
affinity, well-protected and redox-shielded binding sites of proteins, and in higher 
concentrations they can bind to other putative active sites in proteins involved in 
pathology of various degenerative diseases [84]. While zinc compounds have been 
tested for their probable therapeutic role in overcoming cognitive degeneration, 
Zn2+ ion has also been implicated as a contributor to formation of amyloid plaques 
which act as metal sinks [84]. Such mitochondrial damage and mutations have been 
associated with age related late-onset, non-autosomal dominant AD pathology [85].
4.1 Amyloid-β and oxidative stress
Aβ binds and reduces Fe3+ and Cu2+ in presence of endogenous reducing agents 
to generate H2O2 further producing other partially ROS [86, 87]. Studies have 
revealed the role of metal ions such as Fe, Cu and Zn in inducing Aβ aggregation 
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and oligomerization [88–90]. Brain regions rich in Aβ(1–42) show increased oxida-
tive stress, possibly mediated through redox interactions with the only methionine 
(Met35) present in peptide sequence [91]. Amyloids oligomers can also trigger ROS 
generation [2]. The three histidine residues-His6, His13 and His14, facilitate Aβ 
coordination with transition metal ions. These residues get protonated in acidic envi-
ronment and may increasingly contribute to aggregation at low pH. Cu2+ interacts 
with Aβ and oxidizes sulfur of Met35 to activate formation of disulfide bonds leading 
to dimerization and other oligomeric formations. Soluble oxidized aggregates avoid 
clearance causing enrichment of brain regions with these agglomerates. Aβ peptides 
can successfully recruit ions of metals like Fe, Cu and Zn through sulfide group of 
Met35 and a chelating domain which involves Asp1 and all three histidines, in a bid 
to induce redox complexes capable of bringing about oxidative insults [7]. Dityrosine 
cross-linked Aβ dimers along with nitrotyrosine cross-linked proteins are also associ-
ated with oxidative stress [92]. Cell death from oxidative stress is a cumulative result 
of alteration in proteostasis, protein phosphorylation and glucose metabolism as 
downstream consequences of increase in Aβ42 concentration [91].
4.2 Pathophysiology of ROS
Excessive free radical production as a result of oxidative stress at cellular levels 
causes protein oxidation and lipid peroxidation [91]. Lipid peroxidation leads to 
break down of unsaturated fatty acids among other components of membrane 
phospholipids, leading to accumulation of isoprostanes, acrolein, thiobarbiturate-
reactive substances, etc. [84, 92]. Glutamate receptors overstimulation can trigger 
downstream cell death cascades through increased calcium influx and generation 
of nitric oxide species [48]. 8-hydroxy-2′-deoxyguanosine (OHDG) is one of the 
oxidative markers for DNA, found in PD patients [36]. These products impair 
glucose transport and glutamate uptake, hence contributing to cell apoptosis. ROS 
cause imbalance in metal and ion homeostasis, for example Ca2+, which can trigger 
imbalance in downstream signaling cascades. Oxidative damage can lead to hydrox-
ylation of nucleic acids and carbonylation of proteins. Carbonyls are markers of 
protein oxidation and have been found concentrated in frontal brain regions of AD 
patients [92]. Free radicals generated as result of amyloid oligomerization or aggre-
gation can directly mediate mitochondrial damage which triggers neuronal death 
through downstream pathways, one of them being cytochrome C reduction [48]. 
OS in PD cases may be a result of deregulation of dopamine-iron redox pathway, 
since αS can alter expression of enzymes indirectly regulating dopamine synthesis 
[84]. αS is also known to directly interact with metal ions causing protein aggrega-
tion. ALS is mainly characterized by loss of motor neurons, which combined with 
SOD mutations diminishing its free radical scavenging abilities can exacerbate the 
impacts to oxidative injury [84]. Oxidative markers localized in plaques and NFTs 
are toxic products such as 3-nitrotyrosine, HNE, pyrraline and pentosidine, while 
metal enriched protein carbonyls including ferritin, catalyst, Cu/Zn-SOD and 
Mn-SOD [93].
4.3 Protective mechanisms from ROS
Chaperones can bind ROS generated as by-product of amyloids and thus prevent 
triggering breakdown of homeostasis. α2-Macroglobulin can directly bind Aβ and 
potentially act as a chaperone in addition to its zinc-binding capabilities which can 
help mitigate redox activity of Aβ [94]. Zn2+ is redox-inert and may be helpful in 
mitigating metal mediated Aβ redox activity. ApoE can mediate Aβ clearance as a 
chaperone depending on specific isoform interactions; ε4 may potentially increase 
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Aβ pathology [95]. ApoE interaction with Aβ is modulated by metals [93]. There are 
two key requirements for metal interactions in dementia-either supplementation 
or chelation [83]. Metal chelators can help solubilization of Aβ plaques. Effects of 
chaperones on metal ions need to be carefully curated to maintain metal homeosta-
sis in brain and other organs of nervous system. Several endogenous brain proteins 
show potential protective response against ROS in diseased brain, including β-trace 
protein, which is the second most abundant protein in CSF. Competitive binding of 
metal ions by chaperone proteins may be advantageous in decreasing generation of 
ROS by-products. Overexpression of metal-affinity proteins have been shown, as 
example of iron-binding ferritin. Antioxidant alpha-tocopherol has been reported 
to potentially slow AD progression in addition to action of metal chelators such as 
clioquinol and desferrioxamine [92]. L-PGDS scavenges ROS and in process pro-
tects against neuronal cell death with its ligand binding function intact [96]. It also 
reduces cytotoxicity mediated by oxidation of heme metabolites such as bilirubin 
[97]. We have found that L-PGDS can directly interact with Aβ-heme complex and 
lower its peroxidase activity (to be published). Other non-proteolytic chaperones 
such as α2M, clusterin and haptoglobin, also show neuroprotective potential in 
similar manner as L-PGDS and are good candidates for more comprehensive oxida-
tive stress related studies.
5. Conclusions
Alzheimer’s disease is a debilitating neurodegenerative condition and is pro-
jected to be a major risk factor for global population by the year 2050 [98]. One 
of the key theories, known as “amyloid cascade hypothesis” postulates that oligo-
merization of amyloid-β (Aβ) in brain is the key pathological event in AD [99]. 
Although complete explanation of causation in AD is yet to be established, it has 
been universally accepted that amyloidosis (perhaps provoked by environmental 
factors) plays a crucial role in AD progression [99–101]. Conformational alterations 
in Aβ which lead to its conversion from soluble peptide to insoluble aggregates 
are considered as a key mechanism in pathogenesis of neurodegenerative diseases 
such as AD [102]. Early amyloid aggregates can act as biomarkers in most dementia 
related maladies and associate observed clinical symptoms to underlying patho-
physiological mechanisms. Till date, we do not have any therapeutic solution for 
aggregation of amyloids. Current gold-standard biomarkers in neurodegeneration 
are neuroimaging systems of degeneration and detectable clinical symptoms repre-
sent pathological changes causing irreversible damage to nervous system [33, 36]. 
Success of theranostic efforts will rely on rational drug design based on a proper 
understanding of molecular structures and mechanisms involved in aggregation. 
Aβ mediates AD pathology through direct inhibition of neuronal interactions 
and signaling cascades, and triggers oxidative stress in the process. Here we have 
discussed mechanisms of action of amyloid chaperones with focus on Aβ chaper-
ones to better understand their modus operandi. Apart from the protein quality 
control machinery and housekeeping complexes responsible for maintaining 
general proteostasis, we have discussed importance of other endogenous chaper-
ones which step up in time of crisis, often as response to stress stimuli. Proteins 
such as L-PGDS, clusterin, α2M have are involved in many physiological processes, 
with elusive function as amyloid chaperones. These proteins can provide alternative 
mechanisms to control amyloid aggregates in events of failure of intracellular Hsp 
complexes and proteasome machinery. Additionally, their affinity to redox active 
components may provide additional protective mechanisms against Aβ mediated 
oxidative stress.
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Aβ amyloid-β
CNS central nervous system
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DARR dipolar assisted rotation resonance
EM electron microscopy
HD Huntington disease
HNE hydroxy-2,3-nonenal
Hsc heat shock cognate
Hsp heat shock protein
HSR heat shock response
IAPP islet amyloid polypeptide
NMDA N-methyl-D-aspartate
NMR nuclear magnetic resonance
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PDB protein data bank
PrP prion protein
REDOR rotational echo double resonance
ROS reactive oxygen species
SOD superoxide dismutase
ssNMR solid state nuclear magnetic resonance
T2D type II diabetes
TEM transmission electron microscopy
TSE transmissible spongiform encephalopathy
Ub ubiquitin
UPR unfolded protein response
UPS ubiquitin proteasome system
αS α synuclein
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